

Accelerated waning of the humoral response to SARS-CoV-2 vaccines in obesity

Agatha A. van der Klaauw¹, Emily C. Horner^{2#}, Pehuén Pereyra-Gerber^{3,4#}, Utkarsh Agrawal^{14#}, William S. Foster¹², Sarah Spencer², Bensi Vergese^{1,6}, Miriam Smith¹, Elana Henning¹, Isobel D. Ramsay^{3,4,9}, Jack A. Smith^{3,4}, Stephane M. Guillaume¹², Hayley J. Sharpe¹², Iain M. Hay^{5,12}, Sam Thompson¹², Silvia Innocentin¹², Lucy H. Booth², Chris Robertson¹³, Colin McCowan¹⁴, Thomas E. Mulroney², Martin J. O'Reilly², Thevinya P. Gurugama², Lihinya P. Gurugama², Maria A. Rust², Alex Ferreira², Soraya Ebrahimi^{7,8}, Lourdes Ceron-Gutierrez^{7,8}, Jacopo Scotucci¹, Barbara Kronsteiner¹⁶, Susanna J. Dunachie¹⁶, Paul Klenerman¹⁶, PITCH Consortium, Adrian J. Park⁸, Francesco Rubino¹⁷, Hannah Stark¹⁰, Nathalie Kingston¹⁰, Rainer Doffinger^{7,8}, Michelle A. Linterman¹², Nicholas J. Matheson^{3,4,9,11#}, Aziz Sheikh^{15#}, I. Sadaf Farooqi^{1#}, James E. D. Thaventhiran^{2#}

¹University of Cambridge Metabolic Research Laboratories and NIHR Cambridge Biomedical Research Centre, Wellcome-Medical Research Council (MRC) Institute of Metabolic Science; ²MRC Toxicology Unit; ³Cambridge Institute of Therapeutic Immunology and Infectious Disease, ⁴Department of Medicine and ⁵Cambridge Institute for Medical Research, University of Cambridge, Cambridge; ⁶NIHR Cambridge Clinical Research Facility, ⁷Departments of Immunology, ⁸Clinical Biochemistry and ⁹Infectious Diseases and ¹⁰NIHR BioResource, Cambridge University Hospitals NHS Foundation Trust, Cambridge; ¹¹NHS Blood and Transplant, Cambridge; ¹²Babraham Institute, Babraham Research Campus, Cambridge; ¹³Department of Mathematics and Statistics, University of Strathclyde; ¹⁴School of Medicine, University of St. Andrew's; ¹⁵Usher Institute, University of Edinburgh; ¹⁶Nuffield Department of Clinical Medicine, University of Oxford; ¹⁷Department of Diabetes, King's College London and Kings College Hospital NHS Foundation Trust, London; all in UK. #These authors contributed equally. Correspondence and reprint requests should be addressed to Sadaf Farooqi at isf20@cam.ac.uk or to James Thaventhiran at jedt2@cam.ac.uk

Running title: Humoral response to SARS-CoV-2 vaccines in obesity

Keywords: Obesity, SARS-CoV-2, Covid-19, vaccine, humoral immunity.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

33 **ABSTRACT**

34 Obesity is associated with an increased risk of severe Covid-19. However, the effectiveness of
35 SARS-CoV-2 vaccines in people with obesity is unknown. Here we studied the relationship
36 between body mass index (BMI), hospitalization and mortality due to Covid-19 amongst 3.5
37 million people in Scotland. Vaccinated people with severe obesity (BMI>40 kg/m²) were
38 significantly more likely to experience hospitalization or death from Covid-19. Excess risk
39 increased with time since vaccination. To investigate the underlying mechanisms, we
40 conducted a prospective longitudinal study of the immune response in a clinical cohort of
41 vaccinated people with severe obesity. Compared with normal weight people, six months
42 after their second vaccine dose, significantly more people with severe obesity had
43 unquantifiable titres of neutralizing antibody against authentic SARS-CoV-2 virus, reduced
44 frequencies of antigen-experienced SARS-CoV-2 Spike-binding B cells, and a dissociation
45 between anti-Spike antibody levels and neutralizing capacity. Neutralizing capacity was
46 restored by a third dose of vaccine, but again declined more rapidly in people with severe
47 obesity. We demonstrate that waning of SARS-CoV-2 vaccine-induced humoral immunity is
48 accelerated in people with severe obesity and associated with increased hospitalization and
49 mortality from breakthrough infections. Given the prevalence of obesity, our findings have
50 significant implications for global public health.

51

52

53

54

55

56

57 **Main**

58 Globally, obesity (defined as a body mass index (BMI) >30 kg/m²) is a major risk factor for
59 severe Covid-19¹. Severe obesity (BMI >40 kg/m²), which affects 3% of the population in the
60 UK and 9% in the US (www.worldobesity.org), is associated with a 90% higher risk of death
61 from Covid-19². Obesity is associated with type 2 diabetes mellitus, hypertension, chronic
62 kidney disease (CKD) and heart failure, co-morbidities which independently increase the risk
63 of severe Covid-19³.

64

65 SARS-CoV-2 vaccines reduce the risk of symptomatic infection, hospitalization and mortality
66 due to Covid-19⁴⁻⁸. They generate antibodies against the Spike (S) protein of SARS-CoV-2,
67 comprising S1 and S2 subunits; S1 contains the receptor binding domain (RBD), which
68 mediates binding of the virus to angiotensin converting enzyme-2 (ACE-2) on host cells. The
69 RBD is the main target for SARS-CoV-2 neutralizing antibodies, which inhibit viral replication *in*
70 *vitro* and correlate with protection against infection *in vivo*⁴⁻⁶. As well as neutralizing
71 antibodies, non-neutralizing antibodies and cellular immunity contribute to protection,
72 particularly against severe Covid-19. Immunity acquired after two doses of vaccine wanes
73 over 6-9 months; many countries have elected to administer booster doses to maintain
74 immune protection, particularly in the elderly and immunocompromised^{9,10}.

75

76 People with obesity have impaired immune responses to conventional influenza, rabies and
77 hepatitis vaccines¹¹⁻¹⁴, however, the impact of obesity on their responses to mRNA and
78 adenoviral vectored vaccines is not known. Some studies have suggested that following SARS-
79 CoV-2 vaccination, antibody titres may be lower in people with obesity¹⁵⁻²⁰. One possible
80 explanation is the impact of needle length on vaccine dosing in people with obesity²¹. To date,

81 longitudinal studies to investigate the duration of protection following SARS-CoV-2
82 vaccination in people with obesity have not been performed.

83

84 **Hospitalization and death due to Covid-19 in vaccinated people**

85 To investigate the real-world effectiveness of SARS-CoV-2 vaccination, we used the EAVE II
86 surveillance platform which draws on near real-time nationwide health care data for 5.4
87 million individuals (~99%) in Scotland, UK²²⁻²⁵. We interrogated data on 3,522,331 individuals
88 aged 18 and over who received a second dose (of the primary vaccination schedule) or a third
89 booster dose of vaccine and were followed up until hospitalization, death or the end of the
90 study. Body mass index (BMI, weight in kg/height in metres squared) was recorded for
91 1,734,710 (49.2%) individuals. We first examined the impact of BMI on Covid-19 related
92 hospitalization and mortality ≥ 14 days after receiving a second dose of either Pfizer-BioNTech
93 BNT162b2 mRNA or AstraZeneca ChAdOx1 nCoV-19 vaccines. Between September 14, 2020
94 and March 19, 2022, there were 10,983 people (0.3%, 6.0 events per 1000 person-years) who
95 had a severe Covid-19 outcome: 9,733 individuals were hospitalized and 2,207 individuals
96 died due to Covid-19 (957 individuals were hospitalized before their death). People with
97 severe obesity (BMI >40 kg/m²) were at increased risk of severe Covid-19 outcomes following
98 a second vaccine dose, compared to those with a BMI in the normal range, with an adjusted
99 Rate Ratio (aRR) of 1.76 (95% Confidence Intervals (CI), 1.60-1.94) after adjusting for age, sex
100 and socioeconomic status (Methods). A modest increase in risk was also seen in people who
101 were obese (BMI 30-40 kg/m²) and those who were underweight (BMI <18.5 kg/m²) (aRR
102 1.11, 95% CI 1.05-1.18 and aRR 1.28, 95% CI 1.12-1.47, respectively) (Table S1 in the Extended
103 Data). People with obesity and severe obesity were at higher risk of hospitalization or death
104 from Covid-19 after both a second (Fig. 1) and third (booster) dose (Fig. S1 in the Extended

105 Data). Breakthrough infections after the second vaccine dose presented sooner in people with
106 severe obesity (10 weeks) and obesity (15 weeks) than in normal weight people (20 weeks)
107 (Fig. 1). To interrogate whether vaccine effectiveness differed over time in people with severe
108 obesity, an interaction test (comparing one model with the interaction terms in it and then a
109 second model without the interaction terms) was performed. This indicated that vaccine
110 effectiveness over time differed across BMI groups with more rapid loss of protection in those
111 with increased BMI ($P < 0.001$).

112

113 Vaccinated individuals who were severely obese and also had type 2 diabetes were at
114 increased risk of admission to hospital or death due to Covid-19 (aRR 1.43, 95% CI 1.17-1.74,
115 Fig. S1f in the Extended Data). A diagnosis of type 2 diabetes was independently associated
116 with an increased risk of a severe Covid-19 outcome despite vaccination (aRR 1.13, 95% CI
117 1.07-1.19), although this was less than the risk associated with severe obesity. The aRR for
118 type 2 diabetes was reduced slightly after adjusting for BMI (1.06, 95% CI 1.00-1.12). Further
119 studies will be needed to test whether hyperglycaemia modifies the risk associated with
120 severe obesity. Cardiovascular disease (stroke, peripheral vascular disease or coronary heart
121 disease), heart failure, asthma, or chronic kidney disease were not significantly associated
122 with a further increase in risk in vaccinated people (Fig. S1f in the Extended Data).

123

124 **Humoral and cellular immunity after primary vaccination**

125 To investigate the mechanisms underlying reduced vaccine efficacy in people with higher BMI,
126 we performed detailed prospective longitudinal immunophenotyping of a clinical cohort of
127 people with severe obesity ($n=28$) and normal weight controls ($n=41$) in Cambridge, UK
128 (SCORPIO study) (Fig. 2a and Table S2 in the Extended Data). All participants had received a

129 two-dose primary course of SARS-CoV-2 vaccine approximately 6 months prior to study
130 enrolment (Fig. 2a). As prior natural SARS-CoV-2 infection enhances subsequent vaccination
131 responses, people with detectable anti-nucleocapsid antibodies (n= 2 with severe obesity; n=
132 1 normal weight control) were excluded. Mean levels of anti-Spike and anti-RBD IgG
133 antibodies were comparable between people with severe obesity and normal weight controls
134 six months after the second vaccine dose (Fig. 2b and Fig. S2a in the Extended Data). In
135 contrast, the function of these antibodies, measured by their ability to neutralize authentic
136 SARS-CoV-2 viral infection (NT50; neutralizing titres at 50% inhibition), was reduced in people
137 with severe obesity (Fig. 2c). In fact, 56% of individuals with severe obesity had unquantifiable
138 neutralizing capacity, compared to 12% of normal weight controls (P=0.0007, Fisher's exact
139 test, Fig. 2d). The observed dissociation between Spike antibody levels and neutralizing
140 capacity could be a consequence of lower antibody affinity, or differential antibody reactivity
141 to non-neutralizing epitopes of the Spike protein. Here, normal levels of RBD-binding
142 antibodies indicate adequate capacity for antibody production against neutralizing epitopes,
143 suggesting a lower affinity of SARS-CoV-2 antibodies in people with severe obesity. Baseline
144 plasma glucose, leptin levels or the presence type 2 diabetes did not correlate with
145 neutralizing capacity in people with severe obesity (Fig. S2b-e in the Extended Data).

146

147 Suboptimal antibody responses may be enhanced by activating memory B-cells, which can
148 rapidly differentiate into antibody-producing plasma cells after booster immunisation.
149 Consistent with the impaired neutralizing antibody response in people with severe obesity,
150 we found a trend towards a reduced frequency of antigen-experienced (IgD-) RBD-binding B
151 cells (P=0.1448, Fig. 2e) and a significantly reduced frequency of antigen-experienced Spike-
152 binding B cells compared to normal weight controls 6 months after second vaccine dose

153 (P=0.038, Fig. 2f). Conversely, antigen-specific T cell responses quantified by ELISpot were
154 comparable in people with severe obesity and normal weight controls (Fig. S2f in the
155 Extended Data).

156

157 **Response to booster vaccination**

158 We next studied the response to a third (booster) dose of mRNA vaccine (BNT162b2 or
159 mRNA1273) in people with severe obesity (n=28) and normal weight controls (n=16). As
160 expected, levels of anti-Spike and anti-RBD IgG antibodies increased markedly at Day 28 (Fig.
161 3a and Fig. S3a in the Extended Data). Surprisingly, peak levels were higher in people with
162 severe obesity than normal weight controls (P=0.0052, Fig. 3a and P=0.0014, Fig. S3a in the
163 Extended Data). This finding argues against vaccine delivery failure in people with obesity due
164 to short needle length²¹ (longer needles are recommended for people with BMI>40kg/m² in
165 the UK) and indicates that a fixed rather than weight-adjusted dosing schedule is appropriate
166 for Covid-19 vaccination. Neutralizing antibody titres were nonetheless comparable between
167 the two groups at Day 28 (Fig. 3b). This suggests that, for a given level of antibodies, there
168 was an overall reduction in neutralizing capacity in people with obesity. Elevated anti-RBD
169 levels suggest that severe obesity does not lead to a failure to target neutralizing Spike
170 epitopes, but rather that the impairment in neutralizing capacity may result from a lack of
171 high-affinity antibodies. All participants generated an NT50 > 100, and 61% (n=17) of
172 participants with severe obesity and 67% (n=8) of normal weight controls generated an NT50
173 > 1,000.

174

175 To better understand the specific impairment in humoral immunity associated with severe
176 obesity, we next used high dimensional spectral flow cytometry to enumerate and phenotype

177 SARS-CoV-2 RBD and Spike binding B cells (Fig. 3c and Figs. S3c-e in the Extended Data).
178 Unsupervised tSNE analysis (t-distributed stochastic neighbour embedding) of RBD-binding
179 (RBD+) B cells showed an expansion of antigen-specific B cells with an antibody secreting cell
180 phenotype (IgD- CD71+ CD38+ CD20) 8 days after the third vaccine dose (Fig. 3d), which was
181 greater in individuals with severe obesity than normal weight controls (Fig. 3e) and consistent
182 with their increased antibody levels. In addition, 28 days after the third vaccine dose,
183 individuals with severe obesity had a lower frequency of Spike-binding atypical memory
184 (CD21- CD11c+) B cells (Fig. 3f), suggesting that the humoral immune response elicited in
185 people with severe obesity differs from that seen in normal weight individuals (Figs. S4a-c in
186 the Extended Data). Interestingly, the number of circulating T follicular helper (Tfh) cells, a
187 circulating biomarker of the germinal centre reaction²⁶, did not differ between groups (Figs.
188 S4d-e in the Extended Data), suggesting that the enhanced expansion of plasmablasts
189 represents the rapid recall of memory B cells to become antibody secreting cells independent
190 of Tfh cell help. Consistent with the absence of changes in Tfh cells, antigen-specific T cell
191 responses quantified by ELISpot, and the number of regulatory T cells were comparable in
192 people with severe obesity and normal weight controls (Fig. S2b, Figs. S4f-g in the Extended
193 Data).

194

195 **Waning of humoral immunity after booster vaccination**

196 The lower neutralizing antibody titres observed in people with severe obesity prior to booster
197 vaccination could reflect a reduction in either the peak response to primary vaccination, or
198 its longevity. We therefore measured longitudinal antibody levels for 105 days (15 weeks)
199 after the third dose of vaccine. We found more rapid waning of anti-Spike and anti-RBD IgG
200 levels and neutralizing antibody titres in individuals with severe obesity (P=0.0057 for

201 percentage change in anti-Spike IgG; P=0.0087 for percentage change in anti-RBD IgG;
202 P=0.0220 for percentage change in NT50; Fig. 4a-c and Figs. S5a-b in the Extended Data). A
203 similar trend was observed in neutralizing capacity against the Omicron variant of SARS-CoV-
204 2 (BA.1) (Fig. S5c in the Extended Data). Conversely, antigen-specific T cell responses
205 quantified by ELISpot remained comparable in people with severe obesity and normal weight
206 controls at day 105 (Fig. 4d). Taken together, these data indicate that severe obesity leads to
207 a failure in the maintenance of humoral immunity following SARS-CoV-2 vaccination,
208 associated with an increased risk of severe Covid-19.

209

210 **Discussion**

211 Obesity is an established risk factor for severe Covid-19². Here, we show that this risk persists
212 even after SARS-CoV-2 vaccination and increases with time after the primary vaccination
213 course. Our studies of over 0.5 million vaccinated people with obesity and >98,000 vaccinated
214 people with severe obesity are consistent with increased BMI leading to a reduction in the
215 maintenance of vaccine-induced immunity and increased breakthrough infections. In keeping
216 with this, we find evidence of reduced neutralizing antibody capacity 6 months after primary
217 vaccination in individuals with severe obesity. These changes in antibody kinetics are
218 associated with altered B cell differentiation, and a dissociation between anti-Spike antibody
219 levels and neutralizing capacity. A similar, relative reduction in neutralizing capacity has
220 previously been observed in patients with severe Covid-19 in other settings^{27,28} and may
221 reflect either lower antibody affinities, or differential targeting of neutralizing and non-
222 neutralizing Spike epitopes.

223

224 Our findings in people with severe obesity are consistent with previous studies showing that
225 the acute immune response to SARS-CoV-2 vaccines is comparable in people with obesity and
226 normal weight people¹⁵⁻²⁰. Some of these studies suggested that the duration of vaccine-
227 induced immunity may be reduced in people with obesity¹⁶⁻¹⁸. These studies all relied on
228 measurements of immunity at a single time-point and used different assays/endpoints (e.g.
229 self-reported home antibody tests¹⁹ or an assumption of effectiveness in those who tested
230 negative for Covid-19 by RT-PCR²⁰). Here, by prospectively measuring B cell and T cell
231 responses as well as neutralizing capacity of antibodies to authentic virus in vaccinated people
232 with severe obesity and normal weight controls over time, we demonstrate that the waning
233 of humoral immunity associated with SARS-CoV-2 vaccines²⁹ is accelerated in people with
234 severe obesity.

235

236 Our data suggest that obesity may lead to a short-lived antibody response. Antibody
237 production after vaccination can occur via two pathways, which differ in terms of quality or
238 longevity³⁰. The first pathway, the extrafollicular response, results in an initial burst of
239 antibodies early after vaccination. This response is short-lived, with no additional
240 diversification of the B cell repertoire, and its contribution to long-term immunity is therefore
241 minimal. The second pathway, the germinal centre (GC) reaction, produces memory B cells
242 and long-lived antibody secreting plasma cells that can persist long-term in the bone marrow.
243 After third dose/booster vaccination, we found people with severe obesity had an increased
244 number of circulating antibody secreting cells which are biomarkers of the extrafollicular
245 pathway, but not circulating Tfh cells which are biomarkers of the germinal centre response²⁶.
246 We therefore hypothesize that in obesity, the extrafollicular pathway is preferred at the
247 expense of the GC pathway, although the mechanism that drives this is not known.

248

249 Several studies in mice and humans have suggested mechanisms by which obesity may impact
250 on immunity and more specifically on vaccine response^{31,32}. Potential contributory factors
251 include dietary constituents such as fatty acids, the infiltration of bone marrow and the spleen
252 by adipocytes and adipose tissue-derived cytokines such as leptin and interleukin-6^{33,34}, which
253 modulate the function of CD4+ T Follicular Helper and B lymphocytes critical for the GC^{35,36}.
254 Obesity is often characterized as a pro-inflammatory state due to the activation of immune
255 cells (particularly macrophages) in adipose tissue^{37,38}. While it has been suggested that the
256 persistence of a chronic pro-inflammatory state in people with obesity may affect their
257 response to immunological challenges such as vaccination, the mechanisms by which such
258 effects may be mediated require further exploration.

259

260 Since people with obesity show a reduction in the maintenance of humoral vaccine responses,
261 additional or more frequent booster doses are likely to be required to maintain protection
262 against Covid-19. Because of the high prevalence of obesity³⁹, this poses a major challenge
263 for health services and vaccine programs around the world.

264

265

266 **References**

267

- 268 1 Popkin, B. M. *et al.* Individuals with obesity and COVID-19: A global perspective on the
269 epidemiology and biological relationships. *Obes Rev* **21**, e13128,
270 doi:10.1111/obr.13128 (2020).

- 271 2 Gao, M. *et al.* Associations between body-mass index and COVID-19 severity in 6.9
272 million people in England: a prospective, community-based, cohort study. *Lancet*
273 *Diabetes Endocrinol* **9**, 350-359, doi:10.1016/S2213-8587(21)00089-9 (2021).
- 274 3 Arbel, R. *et al.* BNT162b2 Vaccine Booster and Mortality Due to Covid-19. *N Engl J Med*
275 **385**, 2413-2420, doi:10.1056/NEJMoa2115624 (2021).
- 276 4 Khoury, D. S. *et al.* Neutralizing antibody levels are highly predictive of immune
277 protection from symptomatic SARS-CoV-2 infection. *Nat Med* **27**, 1205-1211,
278 doi:10.1038/s41591-021-01377-8 (2021).
- 279 5 Edara, V. V. *et al.* Infection and vaccine-induced neutralizing antibody responses to
280 the SARS-CoV-2 B.1.617.1 variant. *bioRxiv*, doi:10.1101/2021.05.09.443299 (2021).
- 281 6 Gilbert, P. B. *et al.* Immune correlates analysis of the mRNA-1273 COVID-19 vaccine
282 efficacy clinical trial. *Science* **375**, 43-50, doi:10.1126/science.abm3425 (2022).
- 283 7 Polack, F. P. *et al.* Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl*
284 *J Med* **383**, 2603-2615, doi:10.1056/NEJMoa2034577 (2020).
- 285 8 Baden, L. R. *et al.* Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J*
286 *Med* **384**, 403-416, doi:10.1056/NEJMoa2035389 (2021).
- 287 9 Katikireddi, S. V. *et al.* Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-
288 19 hospital admissions and deaths over time: a retrospective, population-based
289 cohort study in Scotland and Brazil. *Lancet* **399**, 25-35, doi:10.1016/S0140-
290 6736(21)02754-9 (2022).
- 291 10 Goldberg, Y. *et al.* Waning Immunity after the BNT162b2 Vaccine in Israel. *N Engl J*
292 *Med* **385**, e85, doi:10.1056/NEJMoa2114228 (2021).

- 293 11 Eliakim, A., Schwindt, C., Zaldivar, F., Casali, P. & Cooper, D. M. Reduced tetanus
294 antibody titers in overweight children. *Autoimmunity* **39**, 137-141,
295 doi:10.1080/08916930600597326 (2006).
- 296 12 Painter, S. D., Ovsyannikova, I. G. & Poland, G. A. The weight of obesity on the human
297 immune response to vaccination. *Vaccine* **33**, 4422-4429,
298 doi:10.1016/j.vaccine.2015.06.101 (2015).
- 299 13 Sheridan, P. A. *et al.* Obesity is associated with impaired immune response to influenza
300 vaccination in humans. *Int J Obes (Lond)* **36**, 1072-1077, doi:10.1038/ijo.2011.208
301 (2012).
- 302 14 Banga, N., Guss, P., Banga, A. & Rosenman, K. D. Incidence and variables associated
303 with inadequate antibody titers after pre-exposure rabies vaccination among
304 veterinary medical students. *Vaccine* **32**, 979-983, doi:10.1016/j.vaccine.2013.12.019
305 (2014).
- 306 15 Levin, E. G. *et al.* Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine
307 over 6 Months. *N Engl J Med* **385**, e84, doi:10.1056/NEJMoa2114583 (2021).
- 308 16 Herzberg, J. *et al.* Persistence of Immune Response in Health Care Workers After Two
309 Doses BNT162b2 in a Longitudinal Observational Study. *Front Immunol* **13**, 839922,
310 doi:10.3389/fimmu.2022.839922 (2022).
- 311 17 Yamamoto, S. *et al.* Sex-associated differences between BMI and SARS-CoV-2 antibody
312 titers following the BNT162b2 vaccine. *Obesity (Silver Spring)* **30**, 999-1003,
313 doi:10.1002/oby.23417 (2022).
- 314 18 Papadopoulos, D. *et al.* Predictive Factors for Neutralizing Antibody Levels Nine
315 Months after Full Vaccination with BNT162b2: Results of a Machine Learning Analysis.
316 *Biomedicines* **10**, doi:10.3390/biomedicines10020204 (2022).

- 317 19 Ward, H. *et al.* Population antibody responses following COVID-19 vaccination in
318 212,102 individuals. *Nat Commun* **13**, 907, doi:10.1038/s41467-022-28527-x (2022).
- 319 20 Mallow, C. *et al.* Real world SARS-COV-2 vaccine effectiveness in a Miami academic
320 institution. *Am J Emerg Med* **54**, 97-101, doi:10.1016/j.ajem.2022.01.066 (2022).
- 321 21 Chhabria, S. & Stanford, F. C. A long shot: The importance of needle length in
322 vaccinating patients with obesity against COVID-19. *Vaccine* **40**, 9-10,
323 doi:10.1016/j.vaccine.2021.11.008 (2022).
- 324 22 Mulholland, R. H. *et al.* Cohort Profile: Early Pandemic Evaluation and Enhanced
325 Surveillance of COVID-19 (EAVE II) Database. *Int J Epidemiol* **50**, 1064-1074,
326 doi:10.1093/ije/dyab028 (2021).
- 327 23 Agrawal, U. *et al.* COVID-19 hospital admissions and deaths after BNT162b2 and
328 ChAdOx1 nCoV-19 vaccinations in 2.57 million people in Scotland (EAVE II): a
329 prospective cohort study. *Lancet Respir Med* **9**, 1439-1449, doi:10.1016/S2213-
330 2600(21)00380-5 (2021).
- 331 24 Simpson, C. R. *et al.* Early Pandemic Evaluation and Enhanced Surveillance of COVID-
332 19 (EAVE II): protocol for an observational study using linked Scottish national data.
333 *BMJ Open* **10**, e039097, doi:10.1136/bmjopen-2020-039097 (2020).
- 334 25 Vasileiou, E. *et al.* Investigating the uptake, effectiveness and safety of COVID-19
335 vaccines: protocol for an observational study using linked UK national data. *BMJ Open*
336 **12**, e050062, doi:10.1136/bmjopen-2021-050062 (2022).
- 337 26 Hill, D. L. *et al.* The adjuvant GLA-SE promotes human Tfh cell expansion and
338 emergence of public TCRbeta clonotypes. *J Exp Med* **216**, 1857-1873,
339 doi:10.1084/jem.20190301 (2019).

- 340 27 Garcia-Beltran, W. F. *et al.* COVID-19-neutralizing antibodies predict disease severity
341 and survival. *Cell* **184**, 476-488 e411, doi:10.1016/j.cell.2020.12.015 (2021).
- 342 28 Rees-Spear, C. *et al.* The effect of spike mutations on SARS-CoV-2 neutralization. *Cell*
343 *Rep* **34**, 108890, doi:10.1016/j.celrep.2021.108890 (2021).
- 344 29 Bergwerk, M. *et al.* Covid-19 Breakthrough Infections in Vaccinated Health Care
345 Workers. *N Engl J Med* **385**, 1474-1484, doi:10.1056/NEJMoa2109072 (2021).
- 346 30 Elsner, R. A. & Shlomchik, M. J. Germinal Center and Extrafollicular B Cell Responses
347 in Vaccination, Immunity, and Autoimmunity. *Immunity* **53**, 1136-1150,
348 doi:10.1016/j.immuni.2020.11.006 (2020).
- 349 31 Andersen, C. J., Murphy, K. E. & Fernandez, M. L. Impact of Obesity and Metabolic
350 Syndrome on Immunity. *Adv Nutr* **7**, 66-75, doi:10.3945/an.115.010207 (2016).
- 351 32 Sattar, N., McInnes, I. B. & McMurray, J. J. V. Obesity Is a Risk Factor for Severe COVID-
352 19 Infection: Multiple Potential Mechanisms. *Circulation* **142**, 4-6,
353 doi:10.1161/CIRCULATIONAHA.120.047659 (2020).
- 354 33 Lord, G. M. *et al.* Leptin modulates the T-cell immune response and reverses
355 starvation-induced immunosuppression. *Nature* **394**, 897-901, doi:10.1038/29795
356 (1998).
- 357 34 Eder, K., Baffy, N., Falus, A. & Fulop, A. K. The major inflammatory mediator
358 interleukin-6 and obesity. *Inflamm Res* **58**, 727-736, doi:10.1007/s00011-009-0060-4
359 (2009).
- 360 35 Deng, J. *et al.* The metabolic hormone leptin promotes the function of TFH cells and
361 supports vaccine responses. *Nat Commun* **12**, 3073, doi:10.1038/s41467-021-23220-
362 x (2021).

- 363 36 Spencer, S. *et al.* Loss of the interleukin-6 receptor causes immunodeficiency, atopy,
364 and abnormal inflammatory responses. *J Exp Med* **216**, 1986-1998,
365 doi:10.1084/jem.20190344 (2019).
- 366 37 Hotamisligil, G. S. Inflammation, metaflammation and immunometabolic disorders.
367 *Nature* **542**, 177-185, doi:10.1038/nature21363 (2017).
- 368 38 Saltiel, A. R. & Olefsky, J. M. Inflammatory mechanisms linking obesity and metabolic
369 disease. *J Clin Invest* **127**, 1-4, doi:10.1172/JCI92035 (2017).
- 370 39 Ward, Z. J. *et al.* Projected U.S. State-Level Prevalence of Adult Obesity and Severe
371 Obesity. *N Engl J Med* **381**, 2440-2450, doi:10.1056/NEJMsa1909301 (2019).

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395 **Table 1.** Population characteristics of individuals from EAVE-II who received second and third
 396 doses of a SARS-CoV-2 vaccine

Characteristic	Both vaccines	
	Total vaccination (n, %)	Severe Covid-19 outcome (n, rate per 1000 person-years)
Total	3,588,340 (100.0)	10,938 (6.0)
Sex	Female	1879578 (52.4) 5528 (5.7)
	Male	1708762 (47.6) 5455 (6.2)
Age group (years)	18-49	1634424 (45.5) 2217 (2.5)
	50-64	1021352 (28.5) 2447 (4.6)
	65-79	706617 (19.7) 3331 (9.2)
	80+	225947 (6.3) 2988 (26.8)
BMI (kg/m²)	<18.5	36197 (1.0) 252 (13.7)
	18.5-24.9	456128 (12.7) 1813 (7.7)
	25-29.9	2428889 (67.7) 5599 (4.5)
	30-39.9	568420 (15.8) 2710 (9.3)
	40+	98706 (2.8) 609 (12.2)

397

398 Footnotes: BMI is body mass index in kg/m².

399

400

401

402

403 **Figure Legends**

404

405 **Figure 1. Risk of severe Covid-19 outcomes after primary vaccination and relationship with**
406 **body mass index.**

407 Panels depict the adjusted rate ratios (aRR) for hospitalization or death (severe Covid-19
408 outcomes) with time after the second SARS-CoV-2 vaccine dose for people in each BMI (body
409 mass index) category in the EAVE-II cohort, Scotland. ARR are calculated against baseline risk
410 at 14-69 days after the second vaccine dose. Error bars indicate 95% confidence intervals. The
411 number (N) of people in each BMI category is indicated. Breakthrough infections after the
412 second vaccine dose presented more quickly in people with severe obesity (10 weeks) and
413 obesity (15 weeks) than in normal weight people (20 weeks).

414

415 **Figure 2. SARS-CoV-2 vaccine-induced immunity in people with severe obesity and normal**
416 **weight people six months after primary vaccination.**

417 **a**, Detailed longitudinal immunophenotyping studies were performed on people with severe
418 obesity (green) and normal weight controls (blue). Samples were obtained six months after
419 the second dose of SARS-CoV-2 vaccine (V2) administered as part of their primary vaccination
420 course and at several time-points after the third dose (V3) as indicated. **b**, shows levels of
421 anti-Spike IgG antibodies (MFI, mean fluorescence intensity). **c**, shows neutralizing titres at
422 50% inhibition (NT50) against wild type SARS-CoV-2, with the dotted line indicating the limit
423 of quantitation. **d**, shows the proportion of people in both groups with unquantifiable and
424 quantifiable titres of neutralizing antibodies. **e**, shows the frequency of antigen-experienced
425 (IgD-) Receptor Binding Domain binding (RBD+) and Spike-binding (Spike+) B cells, 6 months
426 after the primary vaccination course; data expressed as a percentage (%) of the total number

427 of lymphocytes. Panels **b, c, e, f**; horizontal bars indicate the median; ns, not significant,
428 *P<0.05, **P<0.01.

429

430 **Figure 3. Immune response to third (booster) dose SARS-CoV-2 vaccination.**

431 People with severe obesity (green) and normal weight controls (blue) were studied at Day 8
432 (D8) and Day 28 (D28) after the third vaccine dose (V3). **a**, shows peak levels (Day 28) of anti-
433 Spike IgG antibodies (MFI, mean fluorescence intensity). **b**, depicts neutralizing titres at 50%
434 inhibition (NT50) against wild type SARS-CoV-2 at days 8 and 28, with the dotted line
435 indicating the limit of quantitation. **c**, is a schematic depicting the differentiation of B cells in
436 response to vaccine administration. **d**, shows the results from high dimensional spectral flow
437 cytometry to enumerate and phenotype SARS-CoV-2 Receptor Binding Domain binding
438 (RBD+) and Spike binding (Spike+) B cells. Unsupervised tSNE (t-distributed stochastic
439 neighbour embedding) analysis of B cells at different time points was performed (Methods).
440 This showed that B cells cluster into groups, identified by cell surface and intracellular proteins
441 annotated on the heat map (lower panel). **e**, depicts the frequency of antibody secreting cells
442 (IgD- CD71+ CD38+ CD20) 8 days after third dose vaccination and **f**, the frequency of Spike-
443 binding (Spike+) atypical memory (CD21- CD11c+) B cells 28 days after the third vaccine dose.
444 Panels **a, b, e, f**; horizontal bars indicate the median; ns, not significant, *P<0.05, **P<0.01.

445

446 **Figure 4: Third dose SARS-CoV-2 vaccine-induced immunity in people with severe obesity.**

447 People with severe obesity (green) and normal weight controls (blue) were studied at day 28
448 and day 105 after the third vaccine dose. **a**, shows the percentage (%) change in anti-Spike
449 IgG antibody levels (MFI, mean fluorescence intensity) and **b**, the % change in anti-Receptor
450 Binding Domain (RBD) IgG antibody levels between these two time-points. **c**, shows the %

451 change in neutralizing titres at 50% inhibition (NT50) against wild type SARS-CoV-2, with the
452 dotted line indicating the limit of quantitation. **d**, shows T cell responses quantified by Elispot.
453 SFU = Interferon gamma spot forming units. Panels **a, b, c, d**; horizontal bar indicates the
454 median. Participants who reported a positive SARS-CoV-2 RT-PCR test between day 28 and
455 105 or who had positive anti-nucleocapsid antibodies at day 105 were excluded from these
456 analyses. ns = non-significant, *P<0.05, **P<0.01.

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475 **ACKNOWLEDGEMENTS**

476 The epidemiological study is part of the EAVE II project. EAVE II is funded by the MRC
477 (MC_PC_19075) with the support of BREATHE—The Health Data Research Hub for
478 Respiratory Health (MC_PC_19004), which is funded through the UK Research and Innovation
479 Industrial Strategy Challenge Fund and delivered through the Health Data Research UK. This
480 research is part of the Data and Connectivity National Core Study, led by Health Data Research
481 UK in partnership with the Office for National Statistics and funded by UK Research and
482 Innovation (grant ref MC_PC_20058) and the National Core Studies - Immunity. Additional
483 support has been provided through Public Health Scotland, the Scottish Government
484 Director-General Health and Social Care and the University of Edinburgh. The original EAVE
485 project was funded by the National Institute for Health Research (NIHR) Health Technology
486 Assessment programme (11/46/23). We thank Dave Kelly from Albasoft (Inverness, UK) for
487 his support with making primary care data available, and Wendy Inglis-Humphrey, Vicky
488 Hammersley, and Laura Brook (University of Edinburgh, Edinburgh, UK) for their support with
489 project management and administration.

490

491 The SCORPIO study was supported by the Medical Research Council (MR/W020564/1, a core
492 award to J.E.T.; MC_UU_0025/12 and MR/T032413/1, an award to N.J.M.) and the Medical
493 Research Foundation (MRF-057-0002-RG-THAV-C0798). Additional support was provided by
494 NHSBT (WPA15-02 to N.J.M.), Addenbrooke's Charitable Trust (900239 to N.J.M.) and the
495 National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre (N.J.M.
496 and I.S.F.) and NIHR BioResource. M.A.L is supported by the Biotechnology and Biological
497 Sciences Research Council (BBS/E/B/000C0427, BBS/E/B/000C0428), and is a Lister Institute
498 Fellow and an EMBO Young Investigator. I.M.H. is supported by a CIMR PhD studentship; H.J.S.

499 by a Sir Henry Dale Fellowship jointly funded by Wellcome and the Royal Society [109407]
500 and a BBSRC institutional programme grant [BBS/E/B/000C0433]. I.S.F. is supported by
501 Wellcome (207462/Z/17/Z), Botnar Fondation, the Bernard Wolfe Health Neuroscience
502 Endowment and a NIHR Senior Investigator Award. The PITCH study was funded by the UK
503 Department of Health and Social Care. S.J.D. is funded by an NIHR Global Research
504 Professorship (NIHR300791). P.K. is an NIHR Senior Investigator and is funded by Wellcome
505 (WT109965MA). We thank the staff of the obesity clinic at Cambridge University Hospitals for
506 their support in recruitment of participants to the SCORPIO study. Clinical studies were
507 performed in the Wellcome-MRC IMS Translational Research Facility (TRF) supported by a
508 Wellcome Major Award [208363/Z/17/Z]) and in the Cambridge NIHR Clinical Research
509 Facility. WHO International Standard 20/136 was a kind gift from Heli Harvala and David
510 Roberts (NHSBT). The funding bodies had no role in the design or conduct of the study;
511 collection, management, analysis or interpretation of the data; preparation, review or
512 approval of the manuscript or the decision to submit the manuscript for publication. The
513 views expressed are those of the authors and not necessarily those of the NIHR, the
514 Department of Health and Social Care, or the UK government.

515

516 **Author contributions**

517 AAvdK, JEDT and ISF designed and led the study. UA, CM, CR and AS performed the analyses
518 in the EAVE II cohort; AS is the guarantor of this work. AAvdK, SS, MS, BV, EH, JS, AJP, HS, NK,
519 FR and ISF recruited the SCORPIO cohort, performed clinical studies and/or analysed clinical
520 data. ECH co-ordinated laboratory studies including extraction of lymphocytes from clinical
521 samples and T cell assays with SS, LHB, TEM, MJOR, TPG, LPG, MAR, AF; these experiments
522 were overseen by JEDT. NJM provided oversight of studies of neutralizing antibodies with WT

523 and Omicron variants; experiments were performed by PPG with IDR, JAS. RD, SE and LCG
524 performed measurements of anti-S, anti-N antibodies. MAL led experiments of quantitation
525 of lymphocyte types and subsets by flow cytometry including computational analysis (tSNE);
526 these experiments were performed by WSF, SMG, HJS, IMH, ST and SI. BK, SJD, PK and the
527 PITCH Consortium contributed samples from normal weight controls recruited to the PITCH
528 study. All authors approved the final version of the manuscript.

529

530 **Competing interest declaration**

531 AS is a member of the Scottish Government's Standing Committee on Pandemic Preparedness
532 and the Risk Stratification Subgroup of the UK Government's New and Emerging Respiratory
533 Virus Threats Advisory Group (NERVTAG). He was a member of AstraZeneca's Thrombotic
534 Thrombocytopenic Task Force. All roles are unremunerated. SJD is a Scientific Advisor to the
535 Scottish Parliament on COVID-19 for which she receives a fee. All other authors have no
536 conflict of interest to declare.

537

538 **METHODS**

539 **ETHICAL APPROVAL AND STUDY POPULATIONS**

540 **EAVE II study**

541 The EAVE II surveillance platform drew on near real-time nationwide health care data for 5.4
542 million individuals (~99%) in Scotland¹⁻⁴. It includes information on clinical and demographic
543 characteristics of each individual, their vaccination status and type of vaccine used and
544 information on positive SARS-COV-2 infection and subsequent hospitalization or death.
545 Ethical approval was granted by the National Research Ethics Service Committee, Southeast
546 Scotland 02 (reference number: 12/SS/0201) for the study using the Early Pandemic

547 Evaluation and Enhanced Surveillance of Covid-19 (EAVE II) platform. Approval for data
548 linkage was granted by the Public Benefit and Privacy Panel for Health and Social Care
549 (reference number: 1920-0279). Individual written patient consent was not required for this
550 analysis.

551 Using data from the EAVE II platform, we examined the impact of obesity (using BMI
552 measurements), clinical and demographic characteristics including time since receiving the
553 second and third vaccine dose, previous history of testing positive for Covid-19, gap between
554 vaccine doses and dominant variant in the background, of fully vaccinated adults in Scotland
555 who experienced severe Covid-19 outcomes. The cohort analyzed for this study consisted of
556 individuals aged 18 and over who were administered with at least two doses of BNT162b2
557 mRNA, ChAdOx1 nCoV-19 or mRNA-1273 vaccines between December 8, 2020 and March 19,
558 2022. Follow-up began 14 days after receiving the second dose until Covid-19 related
559 hospitalization, Covid-19 related death or the end of study period (i.e., March 19, 2022). All
560 the Covid-19 related hospital admissions or deaths were selected between September 14,
561 2020 and March 19, 2022. Patients without immunosuppression had their primary
562 vaccination schedule with two doses and so the third dose is a booster. For people with
563 immunosuppression, the primary vaccination schedule was for three vaccine doses. BMI was
564 available for individuals based on last recorded measurement within their primary care
565 record. Where the BMI was missing, it was imputed using ordinary least squares regression
566 with all other independent variables included as predictors.

567

568 ***Definition of outcomes***

569 The primary outcome of interest was severe Covid-19, which was defined as Covid-19 related
570 hospital admission or death, 14 days or more after receiving the second vaccine or booster

571 dose⁵. Covid-19 related hospital admission was defined as hospital admission within 14 days
572 of a positive reverse-transcriptase polymerase chain reaction (RT-PCR) test or Covid-19 as
573 reason for admission or a positive SARS-CoV-2 RT-PCR test result during an admission where
574 Covid-19 was not the reason for admission. Covid-19 related mortality was defined as either
575 death for any reason within 28 days of a positive RT-PCR test or where Covid-19 was recorded
576 as the primary reason for death on the death certificate.

577

578 ***Population characteristics and confounders***

579 Characteristics of interest were defined at baseline on December 8, 2020 and included age,
580 sex, socioeconomic status based on quintiles of Scottish Index of Multiple Deprivation (SIMD),
581 urban or rural place of residence, BMI, previous natural infection from SARS-CoV-2 prior to
582 second dose of the vaccine (classified as 0-3 months, 3-6 months, 6-9 months, ≥ 9 months
583 prior to second infection), number of pre-existing comorbidities known to be linked with
584 severe Covid-19 outcome and being in a high risk occupational group defined as someone
585 with undergoing regular RT-PCR testing². BMI was grouped as <18.5 (underweight), 18.5-24.9
586 (normal weight), 25-29.9 (overweight), 30-39.9 (obese) and ≥ 40 kg/m² (severely obese)
587 according to World Health Organization (WHO) criteria.

588

589 ***Statistical analysis EAVE II***

590 We calculated the frequency and rate per 1,000 person-years of severe Covid-19 outcomes
591 for all demographic and clinical factors. Generalized Linear Models (GLM) assuming a Poisson
592 distribution with person-time as an offset representing the time at risk were used to derive
593 rate ratios (RRs) with 95% confidence intervals (CIs) for the association between demographic
594 and clinical factors and Covid-19 related hospitalization or death. Adjusted rate ratios (aRRs)

595 were estimated adjusting for all confounders including age, sex, SIMD, time since receiving
596 the second dose of vaccine, pre-existing comorbidities, the gap between vaccine doses,
597 previous history of SARS-CoV-2 infection and calendar time. R (version 3.6.1) was used to
598 carry out all statistical analyses.

599

600 **SARS-CoV2 vaccination response in obesity (SCORPIO) clinical study**

601 Clinical studies in people with severe obesity and normal weight controls were approved by
602 the National Research Ethics Committee and Health Research Authority (East of England –
603 Cambridge Research Ethics Committee (SCORPIO study, SARS-CoV-2 vaccination response in
604 obesity amendment of “NIHR BioResource” 17/EE/0025)). Each subject provided written
605 informed consent. All studies were conducted in accordance with the Declaration of Helsinki.

606

607 People with severe obesity (class II/ III WHO criteria of BMI ≥ 40 kg/m² or BMI ≥ 35 kg/m²
608 with obesity-associated medical conditions such as type 2 diabetes, hypertension) who
609 attended the obesity clinic at Cambridge University Hospitals NHS Trust and had received two
610 doses of SARS-CoV-2 vaccination (first and second dose of ChAdOX1 nCoV-19 or BNT162b2
611 mRNA) between December 2021 and May 2022, were invited to take part. People with
612 acquired (HIV, immunosuppressant drugs) or congenital immune deficiencies and cancer
613 were excluded. Third dose vaccinations (BNT162b2, Pfizer BioNTech or half dose mRNA1273,
614 Moderna) were administered as part of the NHS vaccination program. UK Health Security
615 Agency policy recommends the use of longer needles (38 vs 25 mm) in people with severe
616 obesity.

617

618 Additional normal weight controls were recruited in Oxford, UK as part of the PITCH study
619 under the GI Biobank Study 16/YH/0247, approved by Yorkshire & Humber Sheffield Research
620 Ethics Committee, which was amended for this purpose on 8 June 2020. Samples obtained 6
621 months after primary course were included.

622

623 Clinical and immunological measurements were taken before the booster vaccination, 8 (-3)
624 days, 28 (+-7) days and 105 (+-7) days after vaccination. Third dose vaccinations were
625 administered as part of the NHS vaccination program and where mRNA vaccines (BNT162b2
626 or mRNA1273 (Moderna). Clinical data regarding co-morbidities associated with obesity was
627 obtained from the medical records. Supplementary Table 3 details the demographic
628 characteristics of this cohort. Healthy healthcare workers were enrolled into the longitudinal
629 OPTIC cohort in Oxford, UK between May 2020 and May 2021 as part of the PITCH
630 consortium. PITCH participants were sampled between July and November 2021, a median of
631 185 days (range 155-223) days after receiving a second vaccination with ChAdOX1 nCoV-19
632 or BNT162b2 mRNA vaccine. All PITCH participants were classified as infection-naïve, as
633 defined by never having received a positive lateral flow or PCR test for SARS-CoV-2, and
634 negative anti-nucleocapsid antibodies at the time of their first vaccination. Therefore, a total
635 of 28 people with severe obesity and 41 normal weight controls were evaluated 6 months
636 after primary course of vaccination, whereas for the response to third dose vaccination, 16
637 normal weight controls were studied.

638

639 Of the 28 recruited people with severe obesity, 2 had positive anti-N antibodies and reported
640 a positive PCR test before their third dose vaccination. They were excluded from further
641 analysis. In addition, between day 28 and 105, 2 people with severe obesity reported positive

642 SARS-CoV-2-tests (lateral flow test or PCR tests as per UK guidelines at the time). They were
643 excluded from the day 28 to day 105 analysis. In addition, one of the normal weight
644 participants had positive anti-N antibodies who had not had a PCR test, before their third dose
645 vaccination. This participant was excluded from the before and after third dose analysis. In
646 addition, between day 28 and 105, 2 normal weight people reported positive SARS-CoV-2-
647 tests (lateral flow test or PCR tests as per UK guidelines at the time, one of those participant
648 on two separate occasions). They have been excluded from the day 28 to day 105 analysis.

649

650 Peripheral blood samples were acquired in either lithium heparin (PBMCs) or serum
651 separating tubes. Serum tubes were centrifuged at 1600 x g for 10 minutes at room
652 temperature (RT) to separate serum from the cell pellet before being aliquoted and stored at
653 -80°C until use. Peripheral blood mononuclear cells (PBMCs) were isolated by layering over
654 lymphoprep density gradient medium (Stemcell Technologies) followed by density gradient
655 centrifugation at 800 x g for 20 minutes at RT. PBMCs were isolated and washed twice using
656 wash buffer (1X PBS, 1% foetal calf serum, 2mM EDTA) at 400 x g for 10 minutes at 4°C.
657 Isolated PBMCs were resuspended in freezing media, aliquoted and stored at -80°C for up to
658 a week before being transferred to liquid nitrogen until use.

659

660 **SARS-CoV-2 serology by multiplex particle-based flow cytometry (Luminex)**

661 Recombinant SARS-CoV-2 anti-nucleocapsid (N), anti-Spike (S) and anti-Receptor-Binding
662 Domain (RBD) antibodies were measured by multiplex particle-based flow cytometry
663 (Luminex)^{6,7}. Recombinant SARS-CoV-2 nucleocapsid (N), spike (S) and receptor-binding
664 domain (RBD) proteins were covalently coupled to distinct carboxylated bead sets (Luminex;
665 Netherlands), forming a 3-plex assay. The S protein construct used is described by Xiong et

666 al⁸, and the RBD construct was described by Stadlbauer et al⁹. The N protein used is a
667 truncated construct of the SARS-CoV-2 N protein comprising residues 48–365 (both ordered
668 domains with the native linker) with an N terminal uncleavable hexahistidine tag. N was
669 expressed in *E. Coli* using autoinducing media for 7h at 37°C and purified using immobilised
670 metal affinity chromatography (IMAC), size exclusion and heparin chromatography. Beads
671 were first activated with 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride
672 (Thermo Fisher Scientific) in the presence of N-hydroxysuccinimide (Thermo Fisher Scientific),
673 according to the manufacturer's instructions, to form amine-reactive intermediates. The
674 activated bead sets were incubated with the corresponding proteins at a concentration of 50
675 µg/ml in the reaction mixture for 3 h at room temperature on a rotator. Beads were washed
676 and stored in a blocking buffer (10 mM PBS, 1% BSA, 0.05% NaN₃). The N-, S- and RBD-coupled
677 bead sets were incubated with patient sera at 3 dilutions (1/100, 1/1000, 1/10000) for 1 h in
678 96-well filter plates (MultiScreen HTS; Millipore) at room temperature in the dark on a
679 horizontal shaker. Fluids were aspirated with a vacuum manifold and beads were washed
680 three times with 10 mM PBS/0.05% Tween 20. Beads were incubated for 30 min with a PE-
681 labeled anti-human IgG-Fc antibody (Leinco/Biotrend), washed as described above, and
682 resuspended in 100 µl PBS/ Tween. They were then analysed on a Luminex analyser (Luminex
683 / R&D Systems) using Exponent Software V31. Specific binding was reported as mean
684 fluorescence intensity (MFI).

685

686 **Neutralizing antibodies to SARS-CoV-2**

687 Neutralization of authentic SARS-CoV-2 virus was measured using reporter cells expressing a
688 protease-activatable luminescent biosensor¹⁰. The SARS-CoV-2 viruses used in this study were
689 a wildtype (lineage B) isolate (SARS-CoV-2/human/Liverpool/REMRQ0001/2020), a kind gift

690 from Ian Goodfellow (University of Cambridge), isolated by Lance Turtle (University of
691 Liverpool), David Matthews and Andrew Davidson (University of Bristol)^{11,12}, and an Omicron
692 (lineage B.1.1.529) variant, a kind gift from Ravindra Gupta¹³.

693

694 Sera were heat-inactivated at 56°C for 30 mins before use, and neutralizing antibody titres at
695 50% inhibition (NT50s) measured as previously described^{10,14}. In brief, luminescent HEK293T-
696 ACE2-30F-PLP2 reporter cells (clone B7) expressing SARS-CoV-2 Papain-like protease-
697 activatable circularly permuted firefly luciferase (FFluc) were seeded in flat-bottomed 96-well
698 plates. The next day, SARS-CoV-2 viral stock (MOI=0.01) was pre-incubated with a 3-fold
699 dilution series of each serum for 2 h at 37°C, then added to the cells. 16 h post-infection, cells
700 were lysed in Bright-Glo Luciferase Buffer (Promega) diluted 1:1 with PBS and 1% NP-40, and
701 FFluc activity measured by luminometry. Experiments were conducted in duplicate.

702

703 To obtain NT50s, titration curves were plotted as FFluc vs log (serum dilution), then analysed
704 by non-linear regression using the Sigmoidal, 4PL, X is log(concentration) function in
705 GraphPad Prism. NT50s were reported when (1) at least 50% inhibition was observed at the
706 lowest serum dilution tested (1:10), and (2) a sigmoidal curve with a good fit was generated.
707 For purposes of visualisation and ranking, samples with no neutralizing activity were assigned
708 an arbitrary NT50 of 2. Samples for which visual inspection of the titration curve indicated
709 inhibition at low dilutions, but which did not meet criteria (1) and (2) above, were assigned
710 an arbitrary NT50 of 4. Unless otherwise indicated, all NT50s shown refer to neutralization of
711 wildtype virus.

712

713 To enable comparison with other studies, the neutralizing capacity of World Health
714 Organisation International Standard 20/136 (WHO IS 20/136) against wildtype SARS-CoV-2
715 was measured in 5 independent experiments, yielding a geometric mean NT50 of 1967 (Fig.
716 S5 in extended data). This standard comprises pooled convalescent plasma obtained from 11
717 individuals which, when reconstituted, is assigned an arbitrary neutralizing capacity of 1000
718 IU/ml against early 2020 SARS-CoV-2 isolates¹⁵. NT50s against wildtype SARS-CoV-2 from this
719 study may therefore be converted to IU/ml using a calibration factor of 1000/1967 (0.51),
720 with a limit of quantitation of 5.1 IU/ml (corresponding to an NT50 of 10).

721

722 **T cell cytokine production**

723 T cell responses were assessed using an ELISpot assay¹⁶. T cell ELISpot assays were performed
724 using the PITCH Standard Operating Procedure¹⁶. Cryopreserved PBMCs were thawed using
725 RPMI media supplemented with 1% (v/v) Penicillin/Streptomycin (Sigma) containing 0.01%
726 (v/v) Benzoase Nuclease (Merck), and then rested for 2-3 hours in RPMI media supplemented
727 with 10% (v/v) Human AB Serum (Sigma) and 1% (v/v) Penicillin/Streptomycin (Sigma) at
728 37°C. Plates precoated with capture antibody (Mabtech, mAb 1-D1K) were washed three
729 times with sterile phosphate buffered saline (PBS) and then blocked with RPMI media
730 supplemented with 10% (v/v) Human AB Serum and 1% (v/v) Penicillin/Streptomycin at 37°C
731 for 1-2 hours. Overlapping peptide pools (18-mers with 10 amino acid overlap. Mimotopes)
732 representing the spike (S), Membrane (M) or nucleocapsid (N) SARS- CoV-2 proteins were
733 added to 200,000 PBMCs/well at a final concentration of 2µg/ml. Pools consisting of CMV,
734 EBV, influenza, and Tetanus toxoid peptides at a final concentration of 2µg/ml (CEFT;
735 Proimmune) and Concanavalin A (Sigma) were used as positive controls. DMSO (Sigma) was

736 used as the negative control at the equivalent concentration to the peptides. Plates were
737 incubated at 37°C, 5% humidity, for 18 hours. Wells were washed with PBS 0.05% (v/v) Tween
738 (Sigma) seven times before incubation for 2 hours at room temperature with the ELISpot PLUS
739 kit biotinylated detection antibody (clone 7-B6-1) diluted in PBS to 1 µg/ml, 50µl per well.
740 Wells were washed with PBS with 0.05% (v/v) Tween, and then incubated with the ELISpot
741 PLUS kit streptavidin-ALP, diluted in PBS to 1µg/ml for 1 hour at room temperature. Wells
742 were washed with PBS 0.05% (v/v) Tween and colour development was carried out using 1-
743 step NBT/BCIP Substrate Solution. 50µl of filtered NBT/BCIP was added to each well for 5
744 minutes at RT. Colour development was stopped by washing the plates with cold tap water.
745 Plates were left to air dry for 48 hours and the scanned and analysed using the AID iSpot
746 Spectrum ELISpot reader (software version 7.0, Autoimmune Diagnostika GmbH, Germany).
747 The average spot count of the control wells were subtracted from the test wells for each
748 sample to quantify the antigen-specific responses. Results are expressed as spot forming units
749 (SFU) per 10⁶ PBMCs. Analysis was completed using GraphPad Prism software version 9.3.1.
750 The comparison of means between groups was performed using two-way, mixed model
751 ANOVA.

752

753 **Quantitation of lymphocyte types and subsets by flow cytometry**

754 ***Generation of fluorescent RBD-specific and Spike-specific B cell probes***

755 BirA and RBD-avi-His plasmids were subcloned in DH5α Competent Cells (Invitrogen™, Cat#
756 18265017) and purified using EndoFree Plasmid Mega Kit (Qiagen, Cat# 12381) following
757 manufacturer's protocols. Then, biotinylated SARS-CoV-2 RBD with C-terminal Avi and
758 hexahistidine tags was expressed by transient co-transfection transfection of RBD-avi-His and
759 BirA expression plasmids in HEK-293F cells (ThermoFisherScientific Cat# R79007) using PEI

760 MAX (Polysciences Cat# 24765). 1.2 L of culture at a density of 1.0×10^6 cells/mL was
761 supplemented with 175 μ M biotin (Sigma-Aldrich Cat# B4501) and transfected with 600 μ g
762 total DNA at a 4:1 ratio (RBD: BirA) using 12 ml PEI MAX (1 mg/mL). Culture medium was
763 harvested 6 days post-transfection and protein purified using Ni-NTA agarose beads (Qiagen
764 Cat# 30210). Eluted protein was further purified by size-exclusion chromatography on a
765 HiLoad Superdex 200 pg 16/600 column (Cytiva Cat# 28989335) equilibrated in 1X PBS. Peak
766 fractions were pooled, concentrated in a 10 kDa MWCO centrifugal filter (Merck Cat#
767 UFC801024) and snap frozen in liquid nitrogen.

768

769 BirA and Spike-avi-His plasmids were subcloned in DH5 α Competent Cells (Invitrogen™, Cat#
770 18265017) and purified using EndoFree Plasmid Mega Kit (Qiagen, Cat# 12381) following
771 manufacturer's protocols. Biotinylated SARS-CoV-2 S protein with C-terminal Avi and
772 hexahistidine tags was expressed by transient co-transfection of S protein and BirA expression
773 plasmids in HEK-293F cells using PEI MAX. Briefly, 400 ml of culture at a density of 1.0×10^6
774 cells/ml was supplemented with 175 μ M biotin and transfected with 400 μ g total DNA at a
775 4:1 ratio (S-protein: BirA) using 600 μ l PEI MAX (1 mg/ml). Culture medium was harvested 6
776 days post-transfection and protein purified using Ni-NTA agarose beads in batch mode. Beads
777 were loaded into a glass gravity column, washed with 20 ml of PBS with 5 mM imidazole,
778 followed by elution of protein in 5 x 1 ml fractions of PBS with 300 mM imidazole. Eluted
779 protein was further purified by size-exclusion chromatography on a HiLoad Superdex 200 pg
780 16/600 column equilibrated in 1X PBS. Peak fractions were pooled, concentrated in a 30 kDa
781 MWCO centrifugal filter (Merck Cat# UFC803024) and snap frozen in liquid nitrogen.

782

783 Monomers were combined with fluorescently labelled streptavidin (BioLegend) at a 3.95:1
784 molecular ratio, to ensure complete tetramerization of streptavidin molecules. RBD was
785 added to streptavidin in 10% increments, with a 10-minute interval between each addition,
786 and was gently mixed throughout the tetramerization process. Tetramerization was carried
787 out at room temperature, before storage at 4°C.

788

789 ***Spectral flow cytometry***

790 RBD-specific and Spike-specific B cells were measured by high dimension flow cytometry¹⁷.
791 For flow cytometry stains a single cell suspension was prepared from cryopreserved PBMC
792 samples as follows: 1mL PBMC samples were defrosted in a 37°C water bath, and then
793 immediately diluted into 9mL of pre-warmed RPMI+10% Fetal Bovine serum (FBS). Cells were
794 washed twice with 10 mL of FACS buffer (PBS containing 2% FBS and 1mM EDTA). Cells were
795 then resuspended in 500uL of FACS buffer and cell numbers and viability were determined
796 using a Countess™ automated cell counter (Invitrogen). 5×10^6 viable cells were transferred
797 to 96-well plates for antibody staining. Cells were then washed once with FACS buffer, and
798 stained with 100 µL of surface antibody mix (including B cell probes) for 2 hours at 4°C. Cells
799 were then washed twice with FACS buffer, and fixed with the eBioscience Foxp3/Transcription
800 Factor Staining Buffer (ThermoFisher #00-5323-00) for 30 min at 4°C. Cells were then washed
801 with 1x eBioscience Foxp3/Transcription Factor Permeabilisation buffer ((ThermoFisher #00-
802 8333-56) twice and stained with intracellular antibody mix in permeabilisation buffer at 4°C
803 overnight. Following overnight staining, samples were washed twice with 1x permeabilisation
804 buffer and once with FACS buffer and acquired on a Cytex™ Aurora. Cells for single colour
805 controls were prepared in the same manner as the fully stained samples. Manual gating of
806 flow cytometry data was done using FlowJo v10.8 software (Tree Star).

807

808 **Statistical analysis SCORPIO study**

809 Analysis was completed using GraphPad Prism software version 9.3.1. The comparison of
810 means or medians between groups was performed using parametric T test or non-parametric
811 Mann-Whitney U test when appropriate. tSNE, FlowSOM and heatmap analysis were
812 performed using R (version 4.1.2) using code that has previously been described ¹⁸.

813

814 **Methods References**

815

816 1 Mulholland, R. H. *et al.* Cohort Profile: Early Pandemic Evaluation and Enhanced
817 Surveillance of COVID-19 (EAVE II) Database. *Int J Epidemiol* **50**, 1064-1074,
818 doi:10.1093/ije/dyab028 (2021).

819 2 Agrawal, U. *et al.* COVID-19 hospital admissions and deaths after BNT162b2 and
820 ChAdOx1 nCoV-19 vaccinations in 2.57 million people in Scotland (EAVE II): a
821 prospective cohort study. *Lancet Respir Med* **9**, 1439-1449, doi:10.1016/S2213-
822 2600(21)00380-5 (2021).

823 3 Simpson, C. R. *et al.* Early Pandemic Evaluation and Enhanced Surveillance of COVID-
824 19 (EAVE II): protocol for an observational study using linked Scottish national data.
825 *BMJ Open* **10**, e039097, doi:10.1136/bmjopen-2020-039097 (2020).

826 4 Vasileiou, E. *et al.* Investigating the uptake, effectiveness and safety of COVID-19
827 vaccines: protocol for an observational study using linked UK national data. *BMJ Open*
828 **12**, e050062, doi:10.1136/bmjopen-2021-050062 (2022).

829 5 Scotland, P. H. *Public Health Scotland COVID-19 & Winter Statistical Report*,
830 <[https://publichealthscotland.scot/media/10853/21-12-15-covid19-](https://publichealthscotland.scot/media/10853/21-12-15-covid19-winter-publication-report.pdf)
831 [winter-publication-report.pdf](https://publichealthscotland.scot/media/10853/21-12-15-covid19-winter-publication-report.pdf)> (2021).

- 832 6 Collier, D. A. *et al.* Age-related immune response heterogeneity to SARS-CoV-2 vaccine
833 BNT162b2. *Nature* **596**, 417-422, doi:10.1038/s41586-021-03739-1 (2021).
- 834 7 Xiong, X. *et al.* A thermostable, closed SARS-CoV-2 spike protein trimer. *Nat Struct Mol*
835 *Biol* **27**, 934-941, doi:10.1038/s41594-020-0478-5 (2020).
- 836 8 Xiong, X. *et al.* A thermostable, closed SARS-CoV-2 spike protein trimer. *Nature*
837 *Structural & Molecular Biology* **27**, 934-941, doi:10.1038/s41594-020-0478-5 (2020).
- 838 9 Stadlbauer, D. *et al.* SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a
839 Serological Assay, Antigen Production, and Test Setup. *Current Protocols in*
840 *Microbiology* **57**, doi:10.1002/cpmc.100 (2020).
- 841 10 Gerber, P. P. *et al.* A protease-activatable luminescent biosensor and reporter cell line
842 for authentic SARS-CoV-2 infection. *PLoS Pathog* **18**, e1010265,
843 doi:10.1371/journal.ppat.1010265 (2022).
- 844 11 Daly, J. L. *et al.* Neuropilin-1 is a host factor for SARS-CoV-2 infection. *Science* **370**, 861-
845 865, doi:10.1126/science.abd3072 (2020).
- 846 12 Patterson, E. I. *et al.* Methods of Inactivation of SARS-CoV-2 for Downstream Biological
847 Assays. *J Infect Dis* **222**, 1462-1467, doi:10.1093/infdis/jiaa507 (2020).
- 848 13 Meng, B. *et al.* Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and
849 fusogenicity. *Nature* **603**, 706-714, doi:10.1038/s41586-022-04474-x (2022).
- 850 14 Bergamaschi, L. *et al.* Longitudinal analysis reveals that delayed bystander CD8+ T cell
851 activation and early immune pathology distinguish severe COVID-19 from mild
852 disease. *Immunity* **54**, 1257-1275 e1258, doi:10.1016/j.immuni.2021.05.010 (2021).
- 853 15 Knezevic, I. *et al.* WHO International Standard for evaluation of the antibody response
854 to COVID-19 vaccines: call for urgent action by the scientific community. *Lancet*
855 *Microbe* **3**, e235-e240, doi:10.1016/S2666-5247(21)00266-4 (2022).

856 16 Angyal, A. *et al.* T-cell and antibody responses to first BNT162b2 vaccine dose in
857 previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre
858 prospective cohort study. *Lancet Microbe* **3**, e21-e31, doi:10.1016/S2666-
859 5247(21)00275-5 (2022).

860 17 Silva-Cayetano, A. *et al.* A booster dose enhances immunogenicity of the COVID-19
861 vaccine candidate ChAdOx1 nCoV-19 in aged mice. *Med (N Y)* **2**, 243-262 e248,
862 doi:10.1016/j.medj.2020.12.006 (2021).




863 18 Pasciuto, E. *et al.* Microglia Require CD4 T Cells to Complete the Fetal-to-Adult
864 Transition. *Cell* **182**, 625-640 e624, doi:10.1016/j.cell.2020.06.026 (2020).

865


866

867

Underweight (BMI <18.5 kg/m², N= 36,197) Normal weight (BMI 18.5 -24.9 kg/m², N= 456,128) Overweight (BMI 25-29.9 kg/m², N=2,428,889)



Obese (BMI 30-39.9 kg/m², N=568,420)



Severely obese (BMI 40+ kg/m², N=98,706)




Figure 1









Figure 2




Figure 3





Figure 4


Supplementary Figure 1: Adjusted rate ratios for hospitalization and death due to Covid-19 in vaccinated people



a-e, Adjusted rate ratios for hospitalization or death following third (booster) doses per BMI category.


Adjusted Rate Ratios (aRR) for hospitalisation or death following third (booster) dose for different body mass index (BMI) categories. Error bars indicate 95% confidence intervals. N indicates number of people in each category. **f**, adjusted rate ratios for hospitalisation and death in severely obese individuals with obesity-associated comorbidities. Error bars indicate 95% confidence intervals.

Supplementary Figure 2: SARS-CoV-2 vaccine-induced immunity in people with severe obesity and normal weight people.




a, Anti-RBD (receptor binding domain) IgG titres are comparable in people with severe obesity (green) and normal weight individuals (blue) 6 months after primary vaccination course ($P=0.5803$ in Mann-Whitney test). Each symbol represents an individual person and line indicates the median; ns, not significant. **b-e**, Correlation between body mass index (BMI), random blood glucose, leptin levels per unit BMI and the presence or absence of type II diabetes and neutralizing capacity (NT50) 6 months after second dose. Non-parametric Spearman's Rho correlations were calculated between NT50 and clinical parameters. Non-parametric Mann-Whitney test was used to compare people with severe obesity without and with diabetes mellitus. Dotted line indicates the limit of quantitation; ns, not significant. **f**, Antigen-specific T cell responses were quantified by ELISpot. Responses were comparable in people with severe obesity (green) and normal weight controls (blue) before and after third dose booster vaccination. Interferon gamma spot forming units (SFU) were quantified. Each symbol represents an individual person and line indicates the median; ns, not significant. V3D0 is before third dose vaccination (V3), V3D8 is 8 days after third dose and V3D28 is 28 days after third dose vaccination.

Supplementary Figure 3: Response to third dose booster vaccination in severe obesity




a, Anti-RBD (Receptor Binding Domain) IgG levels (MFI, mean fluorescence intensity) were higher in people with severe obesity (green) compared to normal weight controls (blue) (** $P=0.0013$ in Mann-Whitney test). Each symbol represents an individual person studied at Day 28; line indicates the median. **b**, Neutralizing antibody titres (NT50) against the Omicron variant of SARS-CoV-2 were markedly reduced compared with wild type virus (Day 28), but no difference was observed between groups. Non-parametric Mann-Whitney test was used to compare people with severe obesity (green) and normal weight controls (blue). Individual values are shown, with the dotted line indicating the limit of quantitation; ns, not significant. **c**, Representative high dimensional spectral flow cytometry analysis in participant with severe obesity. Flow cytometric plots of RBD-binding (Top panels) and Spike-binding (Lower panels) B cells (CD19+) in a patient with severe obesity, prior to (V3D0), eight days after (V3D8) and 28 days after (V3D28) a booster mRNA vaccine. **d**, High-dimensional spectral flow cytometry of SARS-CoV-2 Spike-binding B cells. t-distributed stochastic neighbor embedding (tSNE) and FlowSOM (Flow Self Organizing Maps tool) analyses of multi-parameter flow cytometry of CD19+ Spike-binding B cells from normal weight individuals (Top panels) and participants with severe obesity (Lower panels) prior to (V3D0), eight days after (V3D8) and 28 days after (V3D28) a booster mRNA vaccine. Heatmap of cell surface expression of proteins on different clusters of cells; red indicates high expression, and yellow indicates low expression. **e**, Flow cytometric quantification of Spike-binding B cells that have been activated by the vaccine (IgD-) in normal weight individuals (blue) and participants with severe obesity (green) eight days (V3D8) and 28 days after (V3D28) a booster mRNA vaccine. Each symbol represents an individual person, horizontal bar indicates the median and p-values are from a Mann-Whitney U test.

Supplementary Figure 4: T and B cell response to third dose booster vaccination in severe obesity




a-c, Flow cytometric quantification of RBD-binding or Spike-binding B cells of either a classical memory (**a & b**) or atypical memory (**c**) phenotype in normal weight individuals (blue) and participants with severe obesity (green) 28 days after (V3D28) a third dose mRNA vaccine. Each symbol represents an individual person, horizontal bars indicate the median and p-value is from a Mann-Whitney U test. **d-e**, Flow cytometric quantification of circulating T follicular helper (cTFH) cells (CXCR5+ ICOS+ CD38+ FOXP3- CD25- CD4+ cells) in normal weight individuals (blue) and participants with severe obesity (green) 8 days (**d**) and 28 days (**e**) after a third dose mRNA vaccine. Each symbol represents an individual person, horizontal bars indicate the median and p-value is from a Mann-Whitney U test. **f-g**, Flow cytometric quantification of circulating T regulatory cells (FOXP3+ CD25+ CD4+ cells) in normal weight individuals (blue) and participants with severe obesity (green) 8 days (**f**) and 28 days (**g**) after a third dose mRNA vaccine. Each symbol represents an individual person, horizontal bars indicate the median and p-value is from a Mann-Whitney U test.

Supplementary Figure 5: Neutralizing capacity before and after third vaccine dose.



a, b, Neutralizing capacity (NT50) measured before and 8 days (V3D8), 28 days (V3D28) and 105 days (V3D105) after third dose vaccination (V3) in normal weight controls shown in blue (**a**) and people with severe obesity shown in green (**b**). People who reported a positive SARS-CoV-2 test or had positive N antibodies at any time point were excluded. **c**, NT50 against wild-type SARS-CoV-2 (dark blue and dark green symbols) and Omicron (BA.1) variant (light blue and light green symbols) at day 28 and day 105 post third dose. Each symbol represents an individual person, horizontal bars indicate the median.

Supplementary Figure 6: Neutralizing capacity of WHO International Standard 20/136.



Neutralization curves **(a)** and corresponding NT50s **(b)** for WHO International Standard for anti-SARS CoV-2 immunoglobulin (IS 20/136) against wildtype SARS-CoV-2. Data from 5 independent experiments. Viral stock (MOI=0.01) was pre-incubated with a 3-fold dilution series of heat-inactivated standard before addition to luminescent reporter cells. Firefly luciferase activity was measured by luminometry 16 h post-infection. For each dilution, mean luminescence \pm Standard Error of the Mean is displayed as % maximum. Geometric mean (GM) NT50 \pm 95% confidence intervals are shown, with the dotted line indicating the limit of quantitation.

Supplementary Table 1: Association between BMI and Covid-19 hospitalization or death among individuals from the EAVE II cohort

BMI category (kg/m ²)	Adjusted rate ratios (95% CI)	
	BMI (imputed)	BMI (recorded)
18.5-24.9	1.0	1.0
<18.5	1.28 (1.12-1.47)	1.47 (1.27-1.69)
25-29.9	0.91 (0.86-0.96)	0.92 (0.83-1.01)
30-39.9	1.11 (1.05-1.18)	0.94 (0.84-1.04)
40+	1.76 (1.60-1.94)	1.36 (1.13-1.64)

The frequency and rate per 1,000 person-years of severe Covid-19 outcomes (Covid-19 related hospitalization or death) was calculated. Adjusted rate ratios (aRRs) were estimated adjusting for all confounders including age, sex, Scottish Index of Multiple Deprivation, time since receiving the second dose of vaccine, number of pre-existing comorbidities, the gap between vaccine doses, previous history of SARS-CoV-2 infection and calendar time. Where the BMI was missing, it was imputed using ordinary least squares regression with all other independent variables included as predictors (BMI (imputed)). CI, confidence intervals. BMI=body mass index.

Supplementary Table 2: Characteristics of people with severe obesity and normal weight controls (SCORPIO study)

	PITCH normal weight		
	Normal weight controls (n=16)	controls (V3D0 comparison) (n=25)	Severe obesity (n=28)
Age (mean, range in years)	46 (38-60)	33 (21-59)	54 (37-69)
Sex (F/M)	10/6	19/6	20/8
BMI (mean, range in kg/m ²)	22.9 (18-25)	21.0 (18-25)	47.4 (38-67)
Primary vaccination course (ChadOx1 vs BNT162b2)	10/6	19/6	18/10
Time after second dose of SARS-CoV-2 vaccination (mean, range in days)	183 (140-239)	186 (155-223)	196 (182-215)
Hypertension (number of individuals)	0	1	15
Diabetes mellitus II (number of individuals)	0	0	11
Cardiovascular disease (number of individuals)	0	0	6
Non-alcoholic fatty liver disease (number of individuals)	0	0	2
Obstructive sleep apnoea (number of individuals)	0	0	8